Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced Non-Small-Cell-Lung-Cancer (NSCLC);Tirapazamine, cisplatin und gemcitabine beim fortgeschrittenen nichtkleinzelligen bronchial-karzinom - Eine phase II-studie

Pneumologie

Volumn 58, Issue 12, 2004, Pages 845-849

  Reck, Martin ^a   Von Pawel, J ^b   Nimmermann, C ^b   Groth, G ^a   Gatzemeier, U ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Asklepios Hospital Gauting   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; MITOMYCIN C; PACLITAXEL; SR 259075; TIRAPAZAMINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL HYPOXIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TRIAZINES;

EID: 11244281682     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830056     Document Type: Article

References (34)

1. Globocan-2000. www-dep.iarc.fr/globocan/globocan.html
2. Matthews MJ, Gordon PR. Morphology of Pulmonary and Pleural Malignancies. In: Strauss MJ (Hrsg.). Lung Cancer: Clinical Diagnosis and Treatment. New York: Grune und Stratton, 1977: 49-69
3. Ginsberg RJ, Goldberg M, Waters PE. Surgery in Non-Small-Cell-Lung- Cancer. In: Roth JA, Ruckdeschel JC, Weisenburger TH (Hrsg.). Thoracic Oncology (Edition 2). Philadelphia: W.B. Thaunders Company, 1995: 124-146
4. Non-Small-Cell-Lung-Cancer Collaborative Group. Chemotherapy in non-small-cell-lung cancer: Meta-Analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909
5. Stephens J, Fairlamb D, Cower N et al. The Big Lung Trial (BLT): Determining the value of Cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002; 21: Abstr. 1161
6. Schiller JH, Harrington D, Bellany CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98
7. Kelly K, Crawley J, Bunn Jr PA et al. Randomized phase III trial of Paclitaxel plus Carboplatin versus Vinorelbine plus Cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210-3218
8. Scagliotti GV, DeMarinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002; 20: 4285-4291
9. Denekamp J, Fowler JF, Dische S. The proportion of hypoxic cells in a human tumor. Int J Radiat Oncol Biol Phys 1977; 2: 1227-1228
10. Moulder JE, Rockwell S. Tumor Hypoxia: Its impact on cancer therapy. Cancer Metast Rev 1987; 5: 313-341
11. 2 histography. In: Vaupel PW, Kelleher DK, Gunderoth M (Hrsg.). Tumor Oxygenation. New York: Gustav Fischer, 1995: 220-232
12. Gatenby RA, Coia LA, Richter MP et al. Oxygen tension in human tumors: In vivo mapping using CT-guided probes. Radiology 1985; 156: 211-214
13. Chaplin DJ, Durand RE, Olive PL. Acute Hypoxia in Tumors: Implifications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986; 12: 1279-1282
14. Brown JM. Tumor Hypoxia, Drug Resistance and Metastases. J Natl Cancer Inst 1990; 82: 338-339
15. Zeman EM, Brown JM, Lemon MJ et al. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncology Biol Phys 1986; 12: 1239-1242
16. Baker MA, Zeman EM, Hirst VK et al. Metabolism of SR-4233 by Chinese Hamster Ovary Cells: basis of selective hypoxic cells and toxicity. Cancer Res 1988; 48: 5947-5952
17. Cahill A, White INH. Reductive Metabolism of 3-Amino-1,2,4-Benzotriacine- 1,4-Dioxide (SR-4233) and the induction of unscheduled DNA-Synthesis in red and human derived cell lines. Carcinogenesis 1990; 11: 1407-1411
18. Keohane A, Godden J, Stratford IJ et al. The effects of three bioreductive drugs (Mitomycin C, RSU-1069 and SR-4233) on cell lines selected for their sensitivity to Mitomycin C or ionizing radiation. Br J Cancer 1990; 61: 722-726
19. Tocher JH, Virk NS, Edwards DE. DNA-Damaging effects and Voltametric Studies on the hypoxic cytotoxin 3-Amino-1,2,4-Benzotriacine-1,4-Dioxide, SR-4233, as a function of pH. Biochem Pharmacol 1990; 40: 1405-1410
20. Herman TS, Teicher BA, Coleman CN. Interaction of SR-4233 with Hyperthermia and Radiation in the FSaIIC Murine Fibrosarcoma Tumor System in vitro and in vivo. Cancer Res 1990; 50: 5055-5059
21. Brown JM. SR-4233 (Tirapazamine): A new anticancer drug exploration hypoxia in solid tumor. Br J Cancer 1993; 67: 1163-1170
22. Holden SA, Teicher BA, Ara G et al. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC Murine Sarcoma. J Natl Cancer Inst 1992; 84: 187-193
23. Doric MJ, Brown JM. Potentiation of the anti-cancer effect of Cisplatin by the hypoxic Cytotoxin Tirapazamine. In: Vaupel PW, Kelleher DK, Gunderoth M (Hrsg.). Tumor Oxygenation. Stuttgart: Gustav Fischer Verlag, 1995: 125-135
24. Siemann DW, Hinchman CA. Potentiation of Cisplatin activity by the bioreductive agent Tirapazamine. Radiother Oncol 1998; 47: 215-220
25. Rodriguez GI, Cathcart DM, Devin JA et al. A Phase I/II Dose Escalation Study of intravenously administered Tirapazamine in combination with Cisplatin, in subjects with non-small cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: Abstract 1144
26. Treat J, Belani C, Johnson E et al. A phase II multicentre study of intravenously administered Tirapazamine plus Cisplatin in subjects with non-small cell lung cancer: A phase I/II study amended for phase II investigational sites. Proc Am Soc Clin Oncol 1998; 17: Abstract 472a
27. Miller VA, Ng KK et al. A phase 11 study of the combination of the novel bioreductive agent Tirapazamine with Cisplatin in patients with advanced non-small cell lung cancer. Ann Oncol 1997; 8: 1269-1271
28. Treat J, Johnson E, Langer C et al. Tirapazamine with Cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 1998; 16: 3524-3527
29. Pawel J von, Römeling R von, Gatzemeier U et al. Tirapazamine plus Cisplatin versus Cisplatin in advanced non-small cell lung cancer: A report of the international CATAPULT 1 study group. J Clin Oncol 2000; 18: 1351-1359
30. National Cancer Institute. Cancer Therapy Evaluation Programmes. Common Toxicity Criteria-Version 2.0. http://ctep.cancer.gov/reporting/ctc.html
31. Nimmermann C, Pawel J von, Gatzemeier U. Phase I trial of Tirapazamine in combination with Cisplatin and Gemcitabine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002; 21: Abstract 1335
32. Shephard F, Koschel G, Pawel J von et al. Comparison of Tirazone (Tirapazamine) and Cisplatin versus Etoposide and Cisplatin in advanced non-small cell lung cancer: Final results of the international Phase III CATAPULT II Trial. Lung Cancer 2000; 29 Suppl 1: 28
33. Williamsen SK, Crowly JJ, Lara PN et al. S0003: Paclitaxel/Carboplatin (PC) versus PC and Tirapazamine (PCT) in advanced non-small cell lung cancer. A phase III Southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Oncol 2003: Abstract 2502
34. Rischin D, Peters L, Smith J et al. Preliminary Results Of TROG 98.02-A randomized phase II study of 5-Fluoruracil, Cisplatin and radiation versus Tirapazamine, Cisplatin and Radiation for advanced Squamous Cell Carcinoma of the Head and Neck. Proc Am Soc Clin Oncol 2003: Abstract 1992